Tyrosine kinase inhibitor prolongs progression-free survival in rare neuroendocrine tumour
Lugano, Switzerland, 20 September 2021 - The first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months. The late breaking...
















